Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 57Carcinoma, Hepatocellular 45Colorectal Neoplasms 18Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Esophageal Neoplasms 9Advanced Gastric Cancer 9Biliary Tract Neoplasms 8Pancreatic Neoplasms 6Liver Neoplasms 5Neoplasms 3Neoplasm Metastasis 3Gastrointestinal Neoplasms 3Gastric Adenocarcinoma 3Digestive System Neoplasms 3Recurrence 2Metastatic Gastric Adenocarcinoma 2Locally Advanced Gastric Cancer 2Gastrointestinal Stromal Tumors 2Advanced Esophagus Cancer 2Uterine Cervical Neoplasms 1Stomach Diseases 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Peritoneal Metastases From Gastric Cancer 1Ovarian Neoplasms 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Intestinal Neoplasms 1Immunotherapy Gastrict Cancer 1Immunotherapy 1Hepatic Metastasis of Colorectal Cancer 1

Interventions

camrelizumab 1apatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Gastric Adenocarcinoma × apatinib × Gastrointestinal × Clear all
NCT04572542 2020-10-01

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

The First Affiliated Hospital of Xiamen University

Phase 1/2 Unknown
46 enrolled
Gastrointestinal

Locally Advanced or Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡